首页 > 最新文献

Clinical & Translational Oncology最新文献

英文 中文
SEOM-GEICO Clinical Guidelines on cervical cancer (2023). SEOM-GEICO 宫颈癌临床指南(2023 年)。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-08-31 DOI: 10.1007/s12094-024-03604-3
Luis Manso, Avinash Ramchandani-Vaswani, Ignacio Romero, Luisa Sánchez-Lorenzo, María José Bermejo-Pérez, Purificación Estévez-García, Lorena Fariña-Madrid, Yolanda García García, Marta Gil-Martin, María Quindós

Cervical cancer (CC) is the fourth most common cancer and the fourth leading cause of mortality in women worldwide. It is strongly associated with high-risk human papillomavirus infection. High-income countries that have implemented human papillomavirus (HPV) vaccination and screening programs have seen dramatic reductions in CC incidence, while developing countries where these programs are not available continue to experience high rates of CC deaths. In early-stage CC, the primary treatment is surgery or radiotherapy, whereas concurrent chemo-radiotherapy (CRT) remains the conventional approach in locally advanced stages until the upcoming approval of immunotherapy. The incorporation of immunotherapy in combination with chemotherapy (with or without bevacizumab) in first line and as monotherapy in second line after platinum-based chemotherapy, has significantly increased overall survival (OS) in recurrent or metastatic CC. The purpose of this guideline is to summarize the most relevant evidence in the diagnosis, treatment, and follow-up of CC and to provide evidence-based recommendations for clinical practice.

宫颈癌(CC)是全球第四大最常见癌症,也是导致妇女死亡的第四大原因。它与高危人类乳头瘤病毒感染密切相关。已实施人类乳头瘤病毒(HPV)疫苗接种和筛查计划的高收入国家的宫颈癌发病率大幅下降,而未实施这些计划的发展中国家的宫颈癌死亡率则居高不下。早期CC的主要治疗方法是手术或放疗,而在免疫疗法即将获得批准之前,局部晚期CC的常规治疗方法仍然是同步化疗和放疗(CRT)。免疫疗法与化疗(联合或不联合贝伐单抗)联合应用于一线治疗,以及在铂类化疗后作为单药应用于二线治疗,可显著提高复发或转移性CC的总生存率(OS)。本指南旨在总结CC诊断、治疗和随访方面最相关的证据,并为临床实践提供循证建议。
{"title":"SEOM-GEICO Clinical Guidelines on cervical cancer (2023).","authors":"Luis Manso, Avinash Ramchandani-Vaswani, Ignacio Romero, Luisa Sánchez-Lorenzo, María José Bermejo-Pérez, Purificación Estévez-García, Lorena Fariña-Madrid, Yolanda García García, Marta Gil-Martin, María Quindós","doi":"10.1007/s12094-024-03604-3","DOIUrl":"10.1007/s12094-024-03604-3","url":null,"abstract":"<p><p>Cervical cancer (CC) is the fourth most common cancer and the fourth leading cause of mortality in women worldwide. It is strongly associated with high-risk human papillomavirus infection. High-income countries that have implemented human papillomavirus (HPV) vaccination and screening programs have seen dramatic reductions in CC incidence, while developing countries where these programs are not available continue to experience high rates of CC deaths. In early-stage CC, the primary treatment is surgery or radiotherapy, whereas concurrent chemo-radiotherapy (CRT) remains the conventional approach in locally advanced stages until the upcoming approval of immunotherapy. The incorporation of immunotherapy in combination with chemotherapy (with or without bevacizumab) in first line and as monotherapy in second line after platinum-based chemotherapy, has significantly increased overall survival (OS) in recurrent or metastatic CC. The purpose of this guideline is to summarize the most relevant evidence in the diagnosis, treatment, and follow-up of CC and to provide evidence-based recommendations for clinical practice.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Distinguishing clinical and imaging characteristics of primary central nervous system lymphoma from high-grade glioma and metastatic brain tumors. 区分原发性中枢神经系统淋巴瘤与高级别胶质瘤和转移性脑肿瘤的临床和成像特征。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-31 DOI: 10.1007/s12094-024-03771-3
Qian Hu, Shenyang Zhang, Rui Xue Ma, Fengyi Lu, Qi Zhang, Jia Jing, Hafiz Khuram Raza, Shengli Li, Li Cheng, Zuohui Zhang, Lin He, Wenqing Meng, Hao Chen, Wei Chen

Objective: The purpose of this retrospective analysis was to evaluate the clinical presentations, radiological characteristics, patient outcomes, and therapeutic approaches among individuals diagnosed with primary central nervous system lymphoma (PCNSL), high-grade glioma (HGG), and metastatic brain tumors (METS).

Methods: We assembled a cohort of brain tumor patients from two medical centers, with two oncologists independently reviewing their clinical profiles. A retrospective examination of 87 PCNSL, 87 HGG, and 71 METS cases was performed to assess the aforementioned parameters.

Results: Notable variations were identified in the incidence of epileptic seizures and cognitive impairments between PCNSL and METS patients. Cerebral hemisphere involvement was predominantly observed in HGG and METS cases. PCNSL cases exhibited a higher likelihood of multiple lesions, whereas HGG showed a greater tendency for recurrence. The median survival times were established at 24.3 months for PCNSL, 44.5 months for HGG, and 27.1 months for METS patients. In PCNSL cases, the number of lesions was identified as a significant predictor of mortality (P = 0.008).

Conclusions: Our findings highlight the importance of clinical and imaging features in diagnosing PCNSL, which may present distinct features compared to HGG and METS.

研究目的这项回顾性分析旨在评估原发性中枢神经系统淋巴瘤(PCNSL)、高级别胶质瘤(HGG)和转移性脑肿瘤(METS)患者的临床表现、放射学特征、患者预后和治疗方法:我们从两个医疗中心收集了一批脑肿瘤患者,由两名肿瘤学家独立审查他们的临床资料。我们对 87 例 PCNSL、87 例 HGG 和 71 例 METS 进行了回顾性检查,以评估上述参数:结果:在 PCNSL 和 METS 患者的癫痫发作率和认知障碍方面发现了明显的差异。在HGG和METS病例中主要观察到大脑半球受累。PCNSL 病例出现多个病灶的可能性更高,而 HGG 病例则更容易复发。PCNSL 患者的中位生存时间为 24.3 个月,HGG 患者为 44.5 个月,METS 患者为 27.1 个月。在 PCNSL 病例中,病灶数量被确定为死亡率的重要预测因素(P = 0.008):我们的研究结果强调了临床和影像学特征在诊断 PCNSL 中的重要性,与 HGG 和 METS 相比,PCNSL 可能具有不同的特征。
{"title":"Distinguishing clinical and imaging characteristics of primary central nervous system lymphoma from high-grade glioma and metastatic brain tumors.","authors":"Qian Hu, Shenyang Zhang, Rui Xue Ma, Fengyi Lu, Qi Zhang, Jia Jing, Hafiz Khuram Raza, Shengli Li, Li Cheng, Zuohui Zhang, Lin He, Wenqing Meng, Hao Chen, Wei Chen","doi":"10.1007/s12094-024-03771-3","DOIUrl":"https://doi.org/10.1007/s12094-024-03771-3","url":null,"abstract":"<p><strong>Objective: </strong>The purpose of this retrospective analysis was to evaluate the clinical presentations, radiological characteristics, patient outcomes, and therapeutic approaches among individuals diagnosed with primary central nervous system lymphoma (PCNSL), high-grade glioma (HGG), and metastatic brain tumors (METS).</p><p><strong>Methods: </strong>We assembled a cohort of brain tumor patients from two medical centers, with two oncologists independently reviewing their clinical profiles. A retrospective examination of 87 PCNSL, 87 HGG, and 71 METS cases was performed to assess the aforementioned parameters.</p><p><strong>Results: </strong>Notable variations were identified in the incidence of epileptic seizures and cognitive impairments between PCNSL and METS patients. Cerebral hemisphere involvement was predominantly observed in HGG and METS cases. PCNSL cases exhibited a higher likelihood of multiple lesions, whereas HGG showed a greater tendency for recurrence. The median survival times were established at 24.3 months for PCNSL, 44.5 months for HGG, and 27.1 months for METS patients. In PCNSL cases, the number of lesions was identified as a significant predictor of mortality (P = 0.008).</p><p><strong>Conclusions: </strong>Our findings highlight the importance of clinical and imaging features in diagnosing PCNSL, which may present distinct features compared to HGG and METS.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of a web-based tool for estimating individualized survival curves in glioblastoma using clinical, mRNA, and tumor microenvironment features with fusion techniques. 开发基于网络的工具,利用临床、mRNA 和肿瘤微环境特征与融合技术估算胶质母细胞瘤的个体化生存曲线。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-30 DOI: 10.1007/s12094-024-03739-3
Zunlan Zhao, Yujie Shi, Shouhang Chen, Yan Xu, Fangfang Fu, Chong Li, Xiao Zhang, Ming Li, Xiqing Li

Objective: Glioblastoma (GBM), one of the most common brain tumors, is known for its low survival rates and poor treatment responses. This study aims to create a robust predictive model that integrates multiple feature types, including clinical data, RNA expression, and tumor microenvironment data, using fusion techniques to enhance model performance.

Methods: We obtained data from the SEER database to assess the impact of nine demographic and clinical features on the survival of 58,495 GBM patients and built predictive machine learning models. Additionally, mRNA expression data from 600 GBM patients from TCGA, CGGA, and GEO were analyzed. We used Cox regression and LASSO to create a gene signature, which was compared against 13 published signatures for accuracy. Twenty-one machine learning models were applied to predict survival at multiple time points. Finally, we integrated multiple feature types using fusion techniques and developed a Shiny app to provide survival predictions for GBM patients.

Results: Using the SEER database, we constructed machine learning models based on nine clinical variables: age, gender, marital status, race, tumor site, laterality, surgery, chemotherapy, and radiation therapy. The best-performing model achieved AUC values of 0.775, 0.728, 0.692, and 0.683 for predicting survival at 6, 12, 18, and 24 months in the testing cohort. In the merged TCGA, CGGA, and GEO cohorts, we identified 11 genes to develop predictive models. These 11 genes outperformed 13 other published gene signatures in predicting the prognosis of GBM. When incorporating mRNA features, tumor microenvironment features, and clinical variables into the fusion models, the AUC values for predicting survival at 6, 12, 18, and 24 months were 0.641, 0.624, 0.655, and 0.637, respectively. A user-friendly tool for predicting the survival curve of individual GBM patients is available at https://zzubioinfo.shinyapps.io/mlGBM/ .

Conclusions: Our study provides a web-based tool that includes two modules: one for predicting survival curves using only clinical variables, and another that integrates multiple feature types for more comprehensive predictions.

目的:胶质母细胞瘤(GBM)是最常见的脑肿瘤之一,以生存率低和治疗反应差而闻名。本研究旨在利用融合技术创建一个稳健的预测模型,该模型整合了多种特征类型,包括临床数据、RNA表达和肿瘤微环境数据,以提高模型的性能:我们从 SEER 数据库中获取数据,评估了九种人口统计学和临床特征对 58495 名 GBM 患者生存期的影响,并建立了预测性机器学习模型。此外,我们还分析了来自 TCGA、CGGA 和 GEO 的 600 名 GBM 患者的 mRNA 表达数据。我们使用 Cox 回归和 LASSO 创建了一个基因特征,并将其与 13 个已发表的特征进行了准确性比较。21 个机器学习模型被用于预测多个时间点的生存率。最后,我们利用融合技术整合了多种特征类型,并开发了一款 Shiny 应用,为 GBM 患者提供生存预测:利用 SEER 数据库,我们构建了基于九个临床变量的机器学习模型:年龄、性别、婚姻状况、种族、肿瘤部位、侧位、手术、化疗和放疗。表现最好的模型在预测测试队列中 6、12、18 和 24 个月的生存率方面的 AUC 值分别为 0.775、0.728、0.692 和 0.683。在合并的TCGA、CGGA和GEO队列中,我们确定了11个基因来开发预测模型。这11个基因在预测GBM预后方面的表现优于其他13个已发表的基因特征。将 mRNA 特征、肿瘤微环境特征和临床变量纳入融合模型后,预测 6、12、18 和 24 个月生存率的 AUC 值分别为 0.641、0.624、0.655 和 0.637。用于预测个别 GBM 患者生存曲线的用户友好型工具可在 https://zzubioinfo.shinyapps.io/mlGBM/ .结论:我们的研究提供了一种基于网络的工具,其中包括两个模块:一个模块仅使用临床变量预测生存曲线,另一个模块整合了多种特征类型,可进行更全面的预测。
{"title":"Development of a web-based tool for estimating individualized survival curves in glioblastoma using clinical, mRNA, and tumor microenvironment features with fusion techniques.","authors":"Zunlan Zhao, Yujie Shi, Shouhang Chen, Yan Xu, Fangfang Fu, Chong Li, Xiao Zhang, Ming Li, Xiqing Li","doi":"10.1007/s12094-024-03739-3","DOIUrl":"https://doi.org/10.1007/s12094-024-03739-3","url":null,"abstract":"<p><strong>Objective: </strong>Glioblastoma (GBM), one of the most common brain tumors, is known for its low survival rates and poor treatment responses. This study aims to create a robust predictive model that integrates multiple feature types, including clinical data, RNA expression, and tumor microenvironment data, using fusion techniques to enhance model performance.</p><p><strong>Methods: </strong>We obtained data from the SEER database to assess the impact of nine demographic and clinical features on the survival of 58,495 GBM patients and built predictive machine learning models. Additionally, mRNA expression data from 600 GBM patients from TCGA, CGGA, and GEO were analyzed. We used Cox regression and LASSO to create a gene signature, which was compared against 13 published signatures for accuracy. Twenty-one machine learning models were applied to predict survival at multiple time points. Finally, we integrated multiple feature types using fusion techniques and developed a Shiny app to provide survival predictions for GBM patients.</p><p><strong>Results: </strong>Using the SEER database, we constructed machine learning models based on nine clinical variables: age, gender, marital status, race, tumor site, laterality, surgery, chemotherapy, and radiation therapy. The best-performing model achieved AUC values of 0.775, 0.728, 0.692, and 0.683 for predicting survival at 6, 12, 18, and 24 months in the testing cohort. In the merged TCGA, CGGA, and GEO cohorts, we identified 11 genes to develop predictive models. These 11 genes outperformed 13 other published gene signatures in predicting the prognosis of GBM. When incorporating mRNA features, tumor microenvironment features, and clinical variables into the fusion models, the AUC values for predicting survival at 6, 12, 18, and 24 months were 0.641, 0.624, 0.655, and 0.637, respectively. A user-friendly tool for predicting the survival curve of individual GBM patients is available at https://zzubioinfo.shinyapps.io/mlGBM/ .</p><p><strong>Conclusions: </strong>Our study provides a web-based tool that includes two modules: one for predicting survival curves using only clinical variables, and another that integrates multiple feature types for more comprehensive predictions.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shugoshin 1 expression in various cancers: a potential target for therapy. 舒戈欣 1 在各种癌症中的表达:潜在的治疗靶点。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-30 DOI: 10.1007/s12094-024-03749-1
Indumathi Ankathatti Narayanaswamy, Abhay Kumaraswamy Kattepur, Kalyani Raju, Venkatachalam Perumal, Ravi Ramalingam, Venkateswarlu Raavi

Shugoshin 1 (SGO1) is one of the Shugoshin (guardian spirit) family proteins, which is reported to be majorly involved in the protection of centromeres and proper segregation of chromosomes during cell division. Recent studies found that the altered expression of SGO1 is associated with various cancers and genetic disorders, and suggested as a target for therapy. In the present study, we have reviewed the available literature on SGO1 gene and protein expression in various cancer-cell lines, animal models and cancer patients, and targeting SGO1 with siRNA/shRNA. A significant increase in the expression of SGO1 mRNA and protein levels were observed in prostate, renal, lung, breast, neuroblastoma, leukemia, hepatocellular, and colon cancer-cell lines and the levels were associated with increased cellular proliferation, invasion, and metastasis. The altered SGO1 levels were observed in SGO1 knockout/haploinsufficient mice compared to wild type and the levels were associated with increased chromosome instability and tumorigenesis. Consistent with cell lines, higher SGO1 expression was also observed in tumor tissues of cancer patients compared to adjacent normal tissue and the levels were positively correlated with tumor stage, grade, size, and hormonal status. Higher SGO1 expression was related to resistance to chemotherapeutic agents and the knockdown of SGO1 increased sensitivity to those agents. Furthermore, targeting SGO1 with siRNA/shRNA reduced the expression of SGO1 and proliferation, and induced apoptosis of cancer cells. Overall, the SGO1 expression levels were significantly higher in various cancers, and targeting SGO1 with siRNA and shRNA reduced the levels of SGO1, proliferation and metastasis of cancers.

据报道,舒戈欣 1(SGO1)是舒戈欣(守护神)家族蛋白之一,主要参与细胞分裂过程中中心粒的保护和染色体的正常分离。最近的研究发现,SGO1 的表达改变与多种癌症和遗传疾病有关,并建议将其作为治疗靶点。在本研究中,我们回顾了现有文献中有关 SGO1 基因和蛋白在各种癌细胞系、动物模型和癌症患者中的表达,以及用 siRNA/shRNA 靶向 SGO1 的研究。在前列腺癌、肾癌、肺癌、乳腺癌、神经母细胞瘤、白血病、肝癌和结肠癌细胞系中,我们观察到 SGO1 mRNA 和蛋白水平的表达明显增加,而且其水平与细胞增殖、侵袭和转移的增加有关。与野生型相比,在 SGO1 基因敲除/单倍体不足的小鼠中观察到了 SGO1 水平的改变,而这一水平与染色体不稳定性和肿瘤发生的增加有关。与细胞系一致,在癌症患者的肿瘤组织中也观察到 SGO1 的表达高于邻近的正常组织,而且其水平与肿瘤分期、分级、大小和激素状态呈正相关。SGO1 的高表达与对化疗药物的耐药性有关,而 SGO1 的敲除会增加对这些药物的敏感性。此外,用 siRNA/shRNA 靶向 SGO1 可减少 SGO1 的表达和增殖,并诱导癌细胞凋亡。总之,SGO1在各种癌症中的表达水平都明显较高,而用siRNA和shRNA靶向SGO1可以降低SGO1的水平,减少癌症的增殖和转移。
{"title":"Shugoshin 1 expression in various cancers: a potential target for therapy.","authors":"Indumathi Ankathatti Narayanaswamy, Abhay Kumaraswamy Kattepur, Kalyani Raju, Venkatachalam Perumal, Ravi Ramalingam, Venkateswarlu Raavi","doi":"10.1007/s12094-024-03749-1","DOIUrl":"https://doi.org/10.1007/s12094-024-03749-1","url":null,"abstract":"<p><p>Shugoshin 1 (SGO1) is one of the Shugoshin (guardian spirit) family proteins, which is reported to be majorly involved in the protection of centromeres and proper segregation of chromosomes during cell division. Recent studies found that the altered expression of SGO1 is associated with various cancers and genetic disorders, and suggested as a target for therapy. In the present study, we have reviewed the available literature on SGO1 gene and protein expression in various cancer-cell lines, animal models and cancer patients, and targeting SGO1 with siRNA/shRNA. A significant increase in the expression of SGO1 mRNA and protein levels were observed in prostate, renal, lung, breast, neuroblastoma, leukemia, hepatocellular, and colon cancer-cell lines and the levels were associated with increased cellular proliferation, invasion, and metastasis. The altered SGO1 levels were observed in SGO1 knockout/haploinsufficient mice compared to wild type and the levels were associated with increased chromosome instability and tumorigenesis. Consistent with cell lines, higher SGO1 expression was also observed in tumor tissues of cancer patients compared to adjacent normal tissue and the levels were positively correlated with tumor stage, grade, size, and hormonal status. Higher SGO1 expression was related to resistance to chemotherapeutic agents and the knockdown of SGO1 increased sensitivity to those agents. Furthermore, targeting SGO1 with siRNA/shRNA reduced the expression of SGO1 and proliferation, and induced apoptosis of cancer cells. Overall, the SGO1 expression levels were significantly higher in various cancers, and targeting SGO1 with siRNA and shRNA reduced the levels of SGO1, proliferation and metastasis of cancers.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic accuracy of imaging modalities for detection of spinal metastases: a systematic review and meta-analysis. 检测脊柱转移瘤的成像模式诊断准确性:系统综述和荟萃分析。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-29 DOI: 10.1007/s12094-024-03765-1
Netanja I Harlianto, Simone van der Star, Britt B M Suelmann, Pim A de Jong, Jorrit-Jan Verlaan, Wouter Foppen

Purpose: Detecting spinal metastases is highly relevant in patients with oncological disorders as it can affect the staging and treatment of their disease. We aimed to evaluate the diagnostic performance of computed tomography (CT), magnetic resonance imaging (MRI), FDG positron emission tomography (PET)/CT, bone scintigraphy (BS), and single-photon emission computed tomography (SPECT) for spinal metastases detection.

Methods: Medline, EMBASE, and Web of Science were systematically searched until March 2024 for diagnostic accuracy studies on spinal metastases detection (PROSPERO-registration: CRD42024540139). Data extraction and quality assessment using the QUADAS-2 tool were performed by two independent reviewers. Using bivariate random effects modeling, pooled sensitivities, specificities, and diagnostic odds ratios (DOR) were calculated, and hierarchical summary operating curves were constructed.

Results: Twenty-five studies (49 datasets), encompassing 3102 patients were included. Per-patient pooled sensitivities of CT, MRI, PET/CT, BS and SPECT were 70%, 93%, 82%, 75%, and 84%, respectively. Pooled specificities were 74%, 85%, 75%, 92%, and 81%, respectively. Per-lesion pooled sensitivities of CT, MRI, PET/CT, BS and SPECT were 76%, 91%, 92%, 77%, and 92%, respectively. Pooled specificities were 91%, 94%, 85%, 52%, and 86%, respectively. MRI had the highest DOR in per patient and lesion analyses.

Conclusion: MRI had highest diagnostic accuracy for spinal metastases detection on patient and lesion level, suggesting a broader use in addition to the routine staging CT, at least in patients at high risk and where the detection of a spinal metastasis could alter therapy decisions. Herein, results should be considered with the limitations of each modality.

目的:脊柱转移瘤的检测与肿瘤患者的病情息息相关,因为它可能影响患者的疾病分期和治疗。我们旨在评估计算机断层扫描(CT)、磁共振成像(MRI)、FDG 正电子发射断层扫描(PET)/CT、骨闪烁扫描(BS)和单光子发射计算机断层扫描(SPECT)对脊柱转移瘤检测的诊断性能:在 2024 年 3 月之前,系统检索了 Medline、EMBASE 和 Web of Science 中有关脊柱转移瘤检测诊断准确性的研究(PROSPERO 注册:CRD42024540139)。由两名独立审稿人使用 QUADAS-2 工具进行数据提取和质量评估。使用双变量随机效应模型计算汇总的敏感性、特异性和诊断几率比(DOR),并构建分层汇总工作曲线:共纳入 25 项研究(49 个数据集),涵盖 3102 名患者。CT、MRI、PET/CT、BS 和 SPECT 对每位患者的集合敏感性分别为 70%、93%、82%、75% 和 84%。集合特异性分别为 74%、85%、75%、92% 和 81%。CT、MRI、PET/CT、BS 和 SPECT 的每病灶集合敏感性分别为 76%、91%、92%、77% 和 92%。集合特异性分别为 91%、94%、85%、52% 和 86%。结论:磁共振成像对每位患者和每个病灶的分析特异性最高:结论:磁共振成像对患者和病灶水平的脊柱转移瘤检测具有最高的诊断准确性,这表明除了常规的分期 CT 外,磁共振成像还可广泛应用于高危患者,因为脊柱转移瘤的检测可能会改变治疗决策。因此,在考虑结果时应考虑到每种模式的局限性。
{"title":"Diagnostic accuracy of imaging modalities for detection of spinal metastases: a systematic review and meta-analysis.","authors":"Netanja I Harlianto, Simone van der Star, Britt B M Suelmann, Pim A de Jong, Jorrit-Jan Verlaan, Wouter Foppen","doi":"10.1007/s12094-024-03765-1","DOIUrl":"https://doi.org/10.1007/s12094-024-03765-1","url":null,"abstract":"<p><strong>Purpose: </strong>Detecting spinal metastases is highly relevant in patients with oncological disorders as it can affect the staging and treatment of their disease. We aimed to evaluate the diagnostic performance of computed tomography (CT), magnetic resonance imaging (MRI), FDG positron emission tomography (PET)/CT, bone scintigraphy (BS), and single-photon emission computed tomography (SPECT) for spinal metastases detection.</p><p><strong>Methods: </strong>Medline, EMBASE, and Web of Science were systematically searched until March 2024 for diagnostic accuracy studies on spinal metastases detection (PROSPERO-registration: CRD42024540139). Data extraction and quality assessment using the QUADAS-2 tool were performed by two independent reviewers. Using bivariate random effects modeling, pooled sensitivities, specificities, and diagnostic odds ratios (DOR) were calculated, and hierarchical summary operating curves were constructed.</p><p><strong>Results: </strong>Twenty-five studies (49 datasets), encompassing 3102 patients were included. Per-patient pooled sensitivities of CT, MRI, PET/CT, BS and SPECT were 70%, 93%, 82%, 75%, and 84%, respectively. Pooled specificities were 74%, 85%, 75%, 92%, and 81%, respectively. Per-lesion pooled sensitivities of CT, MRI, PET/CT, BS and SPECT were 76%, 91%, 92%, 77%, and 92%, respectively. Pooled specificities were 91%, 94%, 85%, 52%, and 86%, respectively. MRI had the highest DOR in per patient and lesion analyses.</p><p><strong>Conclusion: </strong>MRI had highest diagnostic accuracy for spinal metastases detection on patient and lesion level, suggesting a broader use in addition to the routine staging CT, at least in patients at high risk and where the detection of a spinal metastasis could alter therapy decisions. Herein, results should be considered with the limitations of each modality.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metformin boosts doxorubicin efficacy and increases CD8 + T cell frequency in mouse breast cancer. 二甲双胍提高了多柔比星的疗效,并增加了小鼠乳腺癌 CD8 + T 细胞的频率。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-29 DOI: 10.1007/s12094-024-03764-2
Elaheh Hassani, Sahand Mozzendizaji, Vahid Shafiei-Irannejad, Adel Mohammadzadeh

Purpose: Breast cancer is a leading cause of cancer-related deaths among women worldwide. The presence and function of CD8 + T cells in the tumor microenvironment have been associated with better patient outcomes. Drug toxicity has posed a significant challenge to the clinical implementation of chemotherapy-based strategies in cancer treatment.

Methods: In this study, we employed flow cytometry to investigate the potential synergistic immunomodulatory effects on CD8 + T cells in a mouse model of breast cancer by combining metformin, an anti-diabetic medication, with doxorubicin.

Results: Through flow cytometry analysis, we observed that the combination of the two drugs led to an increased percentage of CD8 + T cells compared to either drug alone. The modulation of HIF-1α and  STAT3 gene expression in the combination group further confirmed the efficacy of this approach.

Conclusions: Our findings suggest that combining metformin with doxorubicin can enhance the anticancer activity of doxorubicin and decrease its cytotoxicity in a 4T1 breast cancer mouse model.

目的:乳腺癌是全球妇女因癌症死亡的主要原因。肿瘤微环境中 CD8 + T 细胞的存在和功能与更好的患者预后有关。药物毒性对基于化疗的癌症治疗策略的临床实施构成了重大挑战:在这项研究中,我们采用流式细胞术研究了抗糖尿病药物二甲双胍与多柔比星联合使用对乳腺癌小鼠模型中 CD8 + T 细胞的潜在协同免疫调节作用:结果:通过流式细胞术分析,我们观察到与单独使用两种药物相比,联合使用两种药物可增加 CD8 + T 细胞的比例。联合用药组中 HIF-1α 和 STAT3 基因表达的调节进一步证实了这种方法的有效性:我们的研究结果表明,在4T1乳腺癌小鼠模型中,二甲双胍与多柔比星联用可增强多柔比星的抗癌活性并降低其细胞毒性。
{"title":"Metformin boosts doxorubicin efficacy and increases CD8 + T cell frequency in mouse breast cancer.","authors":"Elaheh Hassani, Sahand Mozzendizaji, Vahid Shafiei-Irannejad, Adel Mohammadzadeh","doi":"10.1007/s12094-024-03764-2","DOIUrl":"https://doi.org/10.1007/s12094-024-03764-2","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer is a leading cause of cancer-related deaths among women worldwide. The presence and function of CD8 + T cells in the tumor microenvironment have been associated with better patient outcomes. Drug toxicity has posed a significant challenge to the clinical implementation of chemotherapy-based strategies in cancer treatment.</p><p><strong>Methods: </strong>In this study, we employed flow cytometry to investigate the potential synergistic immunomodulatory effects on CD8 + T cells in a mouse model of breast cancer by combining metformin, an anti-diabetic medication, with doxorubicin.</p><p><strong>Results: </strong>Through flow cytometry analysis, we observed that the combination of the two drugs led to an increased percentage of CD8 + T cells compared to either drug alone. The modulation of HIF-1α and  STAT3 gene expression in the combination group further confirmed the efficacy of this approach.</p><p><strong>Conclusions: </strong>Our findings suggest that combining metformin with doxorubicin can enhance the anticancer activity of doxorubicin and decrease its cytotoxicity in a 4T1 breast cancer mouse model.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IORT-photon boost plus hypofractionated whole breast irradiation in patients with breast cancer after primary systemic treatment: feasibility, safety and clinical results. 在乳腺癌患者中进行IORT-光子增量加低分量全乳腺照射:可行性、安全性和临床结果。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-28 DOI: 10.1007/s12094-024-03759-z
J Burgos-Burgos, V Vega, D Macias-Verde, E Vicente, C Murias, C Santana, P C Lara

Aim: To assess for the first time the safety and feasibility of combining photon-intraoperative radiotherapy (ph-IORT) with hypofractionated whole breast irradiation (h-WBI) in patients referred to primary systemic therapy (PST).

Methods: From March 2019 to December 2020, patients referred for breast conservative surgery (BCS) after PST in our institution were prospectively included in the present trial. PST was prescribed to all patients according the ESMO-SEOM guidelines. Once the PST was completed, BCS was discussed in the multidisciplinary tumor board (MTB). 20 Gy were prescribed to the surface of the applicator of an Intrabeam®photon-IORT during BCS. h-WBI (40.5 Gy/2.67 Gy/15frx) was planned to be administered 3-5w after BCS. All patients were treated with hWBI VMAT-Rapid-Arc&Daily Exac-Trac-IGRT. The primary end points of the study were feasibility and safety (grade 3 toxicity rate CTCAE.5.0-scale) of the proposed treatment protocol. The secondary end points included cosmetic results (Harvard Scale), local relapse rate and overall survival.

Results: Thirty-five patients were included in the trial. The median age was 54 years. Tumor size was > 2 cm in all cases. Eighteen patients were N + (51.4%). There was no disease progression during PST. All patients received the planned 20 Gy-ph-IORT boost at the time of BCS and the proposed h-WBI. 31/35 (88,6%) patients started h-WBI within the predefined time period (3-5w after BCS). No patient showed ≥ G3 acute toxicity 3 months after the end of h-WBI. No ≥ G3 late toxicity was observed at 12 months of follow-up and thereafter. Cosmetic results were scored excellent/good in 26 patients (74.2%). After a median follow-up of 52 months, a TNBC patient locally relapsed at 13 months of follow-up.

Conclusion: We demonstrated for the first time that ph-IORT + hWBI is feasible and safe in patients referred to BCS after PST.

目的:首次评估光子术中放疗(ph-IORT)与低分次全乳腺照射(h-WBI)在转诊至原发性系统治疗(PST)患者中的安全性和可行性:方法:2019年3月至2020年12月,我院将PST后转诊接受乳腺保守手术(BCS)的患者纳入本试验的前瞻性研究。所有患者均根据ESMO-SEOM指南接受PST治疗。PST 结束后,多学科肿瘤委员会(MTB)讨论 BCS。计划在 BCS 结束后 3-5w 施用 h-WBI(40.5 Gy/2.67 Gy/15frx)。所有患者都接受了 hWBI VMAT-Rapid-Arc&Daily Exac-Trac-IGRT 治疗。研究的主要终点是拟议治疗方案的可行性和安全性(3 级毒性率 CTCAE.5.0 级)。次要终点包括美容效果(哈佛量表)、局部复发率和总生存率:试验共纳入 35 名患者。中位年龄为 54 岁。所有病例的肿瘤大小均大于 2 厘米。18例患者为N +(51.4%)。PST期间没有出现疾病进展。所有患者在进行 BCS 和拟议的 h-WBI 时都接受了计划的 20 Gy-ph-IORT 增强治疗。31/35(88.6%)名患者在预定时间内(BCS 后 3-5w )开始了 h-WBI。h-WBI 结束 3 个月后,没有患者出现≥ G3 急性毒性。在 12 个月的随访及其后,未观察到≥ G3 的后期毒性。26名患者(74.2%)的美容效果被评为优/良。中位随访52个月后,一名TNBC患者在随访13个月时局部复发:我们首次证明了 ph-IORT + hWBI 在 PST 后转诊至 BCS 的患者中是可行且安全的。
{"title":"IORT-photon boost plus hypofractionated whole breast irradiation in patients with breast cancer after primary systemic treatment: feasibility, safety and clinical results.","authors":"J Burgos-Burgos, V Vega, D Macias-Verde, E Vicente, C Murias, C Santana, P C Lara","doi":"10.1007/s12094-024-03759-z","DOIUrl":"https://doi.org/10.1007/s12094-024-03759-z","url":null,"abstract":"<p><strong>Aim: </strong>To assess for the first time the safety and feasibility of combining photon-intraoperative radiotherapy (ph-IORT) with hypofractionated whole breast irradiation (h-WBI) in patients referred to primary systemic therapy (PST).</p><p><strong>Methods: </strong>From March 2019 to December 2020, patients referred for breast conservative surgery (BCS) after PST in our institution were prospectively included in the present trial. PST was prescribed to all patients according the ESMO-SEOM guidelines. Once the PST was completed, BCS was discussed in the multidisciplinary tumor board (MTB). 20 Gy were prescribed to the surface of the applicator of an Intrabeam®photon-IORT during BCS. h-WBI (40.5 Gy/2.67 Gy/15frx) was planned to be administered 3-5w after BCS. All patients were treated with hWBI VMAT-Rapid-Arc&Daily Exac-Trac-IGRT. The primary end points of the study were feasibility and safety (grade 3 toxicity rate CTCAE.5.0-scale) of the proposed treatment protocol. The secondary end points included cosmetic results (Harvard Scale), local relapse rate and overall survival.</p><p><strong>Results: </strong>Thirty-five patients were included in the trial. The median age was 54 years. Tumor size was > 2 cm in all cases. Eighteen patients were N + (51.4%). There was no disease progression during PST. All patients received the planned 20 Gy-ph-IORT boost at the time of BCS and the proposed h-WBI. 31/35 (88,6%) patients started h-WBI within the predefined time period (3-5w after BCS). No patient showed ≥ G3 acute toxicity 3 months after the end of h-WBI. No ≥ G3 late toxicity was observed at 12 months of follow-up and thereafter. Cosmetic results were scored excellent/good in 26 patients (74.2%). After a median follow-up of 52 months, a TNBC patient locally relapsed at 13 months of follow-up.</p><p><strong>Conclusion: </strong>We demonstrated for the first time that ph-IORT + hWBI is feasible and safe in patients referred to BCS after PST.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment approaches and survival outcomes in elderly colorectal cancer patients: a single-center comparative study. 老年结直肠癌患者的治疗方法和生存结果:一项单中心比较研究。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-28 DOI: 10.1007/s12094-024-03758-0
Beliz Bahar Karaoğlan, Erman Akkuş, Mehmet Kayaalp, Cihangir Akyol, Ayhan Bülent Erkek, Hakan Akbulut, Güngör Utkan

Background: Geriatric patients account for nearly half of new colorectal cancer (CRC) cases. This study compares clinicopathological features, treatments, outcomes, and frailty in elderly (≥ 70) and younger (< 70) CRC patients at our center.

Materials and methods: Patients diagnosed with non-metastatic or de novo metastatic CRC between January 2015 and April 2024 were included. Demographic, pathological, and survival data were retrospectively collected. Analyses were performed using SPSS version 25, with statistical significance set at P < 0.05.

Results: Of the 414 non-metastatic CRC patients, 26.6% were aged ≥ 70. Elderly patients received less perioperative chemotherapy (60% vs. 81.6%, P < 0.001) and had more dose reductions (41.6% vs. 19.2%, P < 0.001). Frailty reduced perioperative chemotherapy in elderly non-metastatic patients (54.5% vs. 92.1%, P < 0.001) but did not affect dose reduction (37.9% vs. 33.3%, P = 0.764) or treatment duration (median 24 weeks for both groups, P = 0.909). In metastatic patients, frailty shortened chemotherapy duration (9.5 vs. 15.5 weeks, P = 0.129). Elderly patients had lower 5- and 8-year overall survival (OS) rates (64.7%, 60.1% vs. 83.0%, 78.8%, P = 0.004). In the de novo metastatic cohort (135 patients), age did not affect OS (19.4 vs. 17.3 months, P = 0.590) or PFS (9.8 vs. 7.5 months, P = 0.209). Rectal cancer (HR: 2.751, P = 0.005) and early chemotherapy termination (HR: 4.138, P < 0.001) worsened OS in non-metastatic CRC, while absence of RAS (HR: 2.043, P = 0.047), BRAF mutations (HR: 8.263, P = 0.010), and metastasectomy (HR: 3.650, P = 0.036) improved OS in metastatic CRC.

Conclusion: Age does not independently worsen CRC survival, though early chemotherapy discontinuation impacts outcomes. Reduced-dose chemotherapy or monotherapy can help minimize adverse effects in elderly patients.

背景:老年患者占新发结肠直肠癌(CRC)病例的近一半。本研究比较了老年患者(≥ 70 岁)和年轻患者的临床病理特征、治疗方法、预后和虚弱程度:纳入2015年1月至2024年4月期间诊断为非转移性或新发转移性 CRC 的患者。回顾性收集人口统计学、病理学和生存数据。使用 SPSS 25 版本进行分析,统计显著性设定为 P 结果:在 414 名非转移性 CRC 患者中,26.6% 的患者年龄≥ 70 岁。老年患者接受围手术期化疗的比例较低(60% vs. 81.6%,P 结论:年龄并不会导致癌症患者的生存率降低:虽然早期停止化疗会影响疗效,但年龄并不会单独导致 CRC 生存率下降。减少化疗剂量或单药治疗有助于将老年患者的不良反应降至最低。
{"title":"Treatment approaches and survival outcomes in elderly colorectal cancer patients: a single-center comparative study.","authors":"Beliz Bahar Karaoğlan, Erman Akkuş, Mehmet Kayaalp, Cihangir Akyol, Ayhan Bülent Erkek, Hakan Akbulut, Güngör Utkan","doi":"10.1007/s12094-024-03758-0","DOIUrl":"https://doi.org/10.1007/s12094-024-03758-0","url":null,"abstract":"<p><strong>Background: </strong>Geriatric patients account for nearly half of new colorectal cancer (CRC) cases. This study compares clinicopathological features, treatments, outcomes, and frailty in elderly (≥ 70) and younger (< 70) CRC patients at our center.</p><p><strong>Materials and methods: </strong>Patients diagnosed with non-metastatic or de novo metastatic CRC between January 2015 and April 2024 were included. Demographic, pathological, and survival data were retrospectively collected. Analyses were performed using SPSS version 25, with statistical significance set at P < 0.05.</p><p><strong>Results: </strong>Of the 414 non-metastatic CRC patients, 26.6% were aged ≥ 70. Elderly patients received less perioperative chemotherapy (60% vs. 81.6%, P < 0.001) and had more dose reductions (41.6% vs. 19.2%, P < 0.001). Frailty reduced perioperative chemotherapy in elderly non-metastatic patients (54.5% vs. 92.1%, P < 0.001) but did not affect dose reduction (37.9% vs. 33.3%, P = 0.764) or treatment duration (median 24 weeks for both groups, P = 0.909). In metastatic patients, frailty shortened chemotherapy duration (9.5 vs. 15.5 weeks, P = 0.129). Elderly patients had lower 5- and 8-year overall survival (OS) rates (64.7%, 60.1% vs. 83.0%, 78.8%, P = 0.004). In the de novo metastatic cohort (135 patients), age did not affect OS (19.4 vs. 17.3 months, P = 0.590) or PFS (9.8 vs. 7.5 months, P = 0.209). Rectal cancer (HR: 2.751, P = 0.005) and early chemotherapy termination (HR: 4.138, P < 0.001) worsened OS in non-metastatic CRC, while absence of RAS (HR: 2.043, P = 0.047), BRAF mutations (HR: 8.263, P = 0.010), and metastasectomy (HR: 3.650, P = 0.036) improved OS in metastatic CRC.</p><p><strong>Conclusion: </strong>Age does not independently worsen CRC survival, though early chemotherapy discontinuation impacts outcomes. Reduced-dose chemotherapy or monotherapy can help minimize adverse effects in elderly patients.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetic profile of ferroptosis in non-small cell lung carcinoma and pharmaceutical options for ferroptosis induction. 非小细胞肺癌铁蛋白沉积症的遗传特征及诱导铁蛋白沉积症的药物选择。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-26 DOI: 10.1007/s12094-024-03754-4
Rohil Jawed, Huma Bhatti, Adnan Khan

Lung cancer (LC) is the leading cause of cancer-related deaths and the second most commonly diagnosed malignancy worldwide. Lung adenocarcinoma (LUAD) and lung squamous cell LC (LUSCC) are the most common subtypes of non-small cell LC (NSCLC). Early diagnosis of LC can be challenging due to a lack of biomarkers. The overall survival (OS) of patients with NSCLC is still poor despite the enormous efforts that have been made to develop novel treatments. Understanding fundamental molecular and genetic mechanisms is necessary to develop new therapeutic approaches for NSCLC. A recently identified type of programmed cell death known as ferroptosis is one potential approach. Ferroptosis causes oxidative damage and the death of cancerous cells by peroxidizing unsaturated phospholipids and accumulating reactive oxygen species (ROS) in an iron-dependent manner. Ferroptosis-related gene (FRG) signatures have recently been evaluated for their ability to predict patient OS and prognosis. These analyses show FRGs are involved in cancer progression, and may serve as promising biomarkers for tumor diagnosis and therapy. Moreover, we summarize the current pharmaceutical options of ferroptosis induction and their underlying molecular mechanism in LC. Therefore, this review aims to provide a comprehensive summary of FRG-based prognostic models, their associated metabolic and signaling pathways, and promising therapeutic options for ferroptosis induction in NSCLC.

肺癌是导致癌症相关死亡的主要原因,也是全球第二大最常见的恶性肿瘤。肺腺癌(LUAD)和肺鳞癌(LUSCC)是非小细胞肺癌(NSCLC)最常见的亚型。由于缺乏生物标志物,LC 的早期诊断具有挑战性。尽管在开发新的治疗方法方面做出了巨大努力,但NSCLC患者的总生存率(OS)仍然很低。要开发出治疗 NSCLC 的新方法,就必须了解基本的分子和遗传机制。最近发现的一种细胞程序性死亡--铁凋亡就是一种潜在的方法。铁变态反应以铁依赖的方式过氧化不饱和磷脂并积累活性氧(ROS),从而导致氧化损伤和癌细胞死亡。最近对铁氧化相关基因(FRG)特征进行了评估,以确定其预测患者OS和预后的能力。这些分析表明,铁突变相关基因参与了癌症的进展,并有可能成为用于肿瘤诊断和治疗的有前途的生物标记物。此外,我们还总结了目前在 LC 中诱导铁突变的药物选择及其潜在的分子机制。因此,本综述旨在全面总结基于FRG的预后模型、其相关的代谢和信号通路,以及NSCLC中铁蛋白诱导的有前景的治疗方案。
{"title":"Genetic profile of ferroptosis in non-small cell lung carcinoma and pharmaceutical options for ferroptosis induction.","authors":"Rohil Jawed, Huma Bhatti, Adnan Khan","doi":"10.1007/s12094-024-03754-4","DOIUrl":"https://doi.org/10.1007/s12094-024-03754-4","url":null,"abstract":"<p><p>Lung cancer (LC) is the leading cause of cancer-related deaths and the second most commonly diagnosed malignancy worldwide. Lung adenocarcinoma (LUAD) and lung squamous cell LC (LUSCC) are the most common subtypes of non-small cell LC (NSCLC). Early diagnosis of LC can be challenging due to a lack of biomarkers. The overall survival (OS) of patients with NSCLC is still poor despite the enormous efforts that have been made to develop novel treatments. Understanding fundamental molecular and genetic mechanisms is necessary to develop new therapeutic approaches for NSCLC. A recently identified type of programmed cell death known as ferroptosis is one potential approach. Ferroptosis causes oxidative damage and the death of cancerous cells by peroxidizing unsaturated phospholipids and accumulating reactive oxygen species (ROS) in an iron-dependent manner. Ferroptosis-related gene (FRG) signatures have recently been evaluated for their ability to predict patient OS and prognosis. These analyses show FRGs are involved in cancer progression, and may serve as promising biomarkers for tumor diagnosis and therapy. Moreover, we summarize the current pharmaceutical options of ferroptosis induction and their underlying molecular mechanism in LC. Therefore, this review aims to provide a comprehensive summary of FRG-based prognostic models, their associated metabolic and signaling pathways, and promising therapeutic options for ferroptosis induction in NSCLC.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142512353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intratumoral microbiota: a new force in the development and treatment of esophageal cancer. 瘤内微生物群:食管癌发展和治疗的新力量。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-25 DOI: 10.1007/s12094-024-03757-1
Tianyang Jing, Dong Tang

Esophageal cancer (EC) ranks among the most prevalent cancers worldwide, with a particularly high incidence in the Asian population. Due to the inconspicuous nature of early symptoms, patients with esophageal cancer are typically diagnosed in the middle to late stages, resulting in suboptimal overall treatment outcomes. Consequently, there is an urgent need to explore and refine therapeutic strategies. Microorganisms have been identified in numerous tumor tissues, including EC, and these microorganisms are referred to as the intratumoral microbiome. Intratumoral microbiota and their metabolic byproducts can influence the progression and treatment of esophageal cancer through various mechanisms, such as modulating tumor cell metabolism and local immune responses. Therefore, the intratumoral microbiota may potentially serve as a target for the treatment of esophageal cancer. This review delineates the composition, origin, and diagnostic significance of intratumoral microbiota in esophageal cancer tissue, and discusses the mechanisms by which intratumoral microbiota contribute to the onset of esophageal cancer. In addition, the impact of intratumoral microbiota on the treatment of esophageal cancer and its intervention measures are also addressed.

食管癌(EC)是全球发病率最高的癌症之一,在亚洲人群中的发病率尤其高。由于早期症状不明显,食管癌患者通常在中晚期才被确诊,导致整体治疗效果不理想。因此,迫切需要探索和完善治疗策略。在包括食管癌在内的许多肿瘤组织中都发现了微生物,这些微生物被称为瘤内微生物组。口腔内微生物群及其代谢副产物可通过多种机制影响食管癌的进展和治疗,如调节肿瘤细胞代谢和局部免疫反应。因此,瘤内微生物群有可能成为治疗食管癌的靶点。本综述阐述了食管癌组织中腔内微生物群的组成、起源和诊断意义,并讨论了腔内微生物群导致食管癌发病的机制。此外,还探讨了腔内微生物群对食管癌治疗的影响及其干预措施。
{"title":"Intratumoral microbiota: a new force in the development and treatment of esophageal cancer.","authors":"Tianyang Jing, Dong Tang","doi":"10.1007/s12094-024-03757-1","DOIUrl":"https://doi.org/10.1007/s12094-024-03757-1","url":null,"abstract":"<p><p>Esophageal cancer (EC) ranks among the most prevalent cancers worldwide, with a particularly high incidence in the Asian population. Due to the inconspicuous nature of early symptoms, patients with esophageal cancer are typically diagnosed in the middle to late stages, resulting in suboptimal overall treatment outcomes. Consequently, there is an urgent need to explore and refine therapeutic strategies. Microorganisms have been identified in numerous tumor tissues, including EC, and these microorganisms are referred to as the intratumoral microbiome. Intratumoral microbiota and their metabolic byproducts can influence the progression and treatment of esophageal cancer through various mechanisms, such as modulating tumor cell metabolism and local immune responses. Therefore, the intratumoral microbiota may potentially serve as a target for the treatment of esophageal cancer. This review delineates the composition, origin, and diagnostic significance of intratumoral microbiota in esophageal cancer tissue, and discusses the mechanisms by which intratumoral microbiota contribute to the onset of esophageal cancer. In addition, the impact of intratumoral microbiota on the treatment of esophageal cancer and its intervention measures are also addressed.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142512354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical & Translational Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1